¹Úö±Ù(Park Cheol-Keun) - Yonsei University College of Medicine Department of Pathology
Á¤¿ìÈñ(Jung Woo-Hee) - Yonsei University College of Medicine Department of Pathology
±¸ÀÚ½Â(Koo Ja-Seung) - Yonsei University College of Medicine Department of Pathology
Abstract
Breast cancer, one of the most common cancers in women, has various treatment modalities. Neoadjuvant therapy (NAT) has been used in many clinical trials because it is easy to evaluate the treatment response to therapeutic agents in a short time period; consequently, NAT is currently a standard treatment modality for large-sized and locally advanced breast cancers, and its use in early-stage breast cancer is becoming more common. Thus, chances to encounter breast tissue from patients treated with NAT is increasing. However, systems for handling and evaluating such specimens have not been established. Several evaluation systems emphasize a multidisciplinary approach to increase the accuracy of breast cancer assessment. Thus, detailed and systematic evaluation of clinical, radiologic, and pathologic findings is important. In this review, we compare the major problems of each evaluation system and discuss important points for handling and evaluating NAT-treated breast specimens.
Å°¿öµå
Breast neoplasms, Neoadjuvant therapy, Pathologic response evaluation
KMID :
1039420160500030173
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
À¯È¿¼º°á°ú(Recomendation)
Pathologic evaluation of residual disease is the most essential component of post-NAT breast cancer evaluation.